臺灣博碩士論文加值系統

伸筋草 (Lycopodii Herba)為中醫治療常用之草藥，文獻指出其具有抗發炎及抗氧化之功效，另有研究指出肥胖之發炎狀態會導致葡萄糖代謝異常，但伸筋草是否有改善肥胖致葡萄糖代謝異常之效果尚不清楚。因此，本研究將探討伸筋草對高脂飲食誘發肥胖大鼠之體重與生化代謝之影響。實驗將組別分為正常飼料組 (C)與高脂飲食組 (F)，先餵食雄性Wistar大鼠高脂飲食27週誘發肥胖後，再將其分為F對照組、添加低劑量 (50 mg/kg BW)伸筋草萃取物組 (L)、添加中劑量(100 mg/kg BW)伸筋草萃取物組 (M)及添加高劑量 (200 mg/kg BW)伸筋草萃取物組 (H)，介入為期12週後進行犧牲，採集血液、心臟、肝臟、腎臟及副睪脂肪組織塊，秤量其臟器重及分析血清空腹血糖、胰島素、脂聯素及瘦素，另分析血清中之發炎指標TNF-α與MCP-1、三酸甘油酯、總膽固醇之濃度及AST與ALT之活性。結果顯示，長期給予高脂飲食之大鼠，其最終體重、體重成長百分比、副睪脂肪重、心臟重、肝臟重、肝功能之AST活性、血糖代謝之血清胰島素、葡萄糖、脂聯素、瘦素濃度、血脂代謝之三酸甘油酯濃度及發炎指標TNF-α、MCP-1之濃度皆顯著高於正常飼料組，表示成功以高脂飲食誘發大鼠形成肥胖，且造成肥胖大鼠體內產生慢性發炎、胰島素阻抗、空腹血糖、血脂濃度異常、肝功能損傷等問題；而給予伸筋草萃取物後可顯著降低高脂誘發肥胖大鼠體重、ALT之活性、空腹血清胰島素、葡萄糖、脂聯素、瘦素濃度、血液三酸甘油酯濃度及發炎指標TNF-α、MCP-1之濃度等生化代謝問題；此外，以高劑量伸筋草介入之效果最為顯著。綜合上述結果可得知，給予高脂誘發肥胖大鼠高劑量伸筋草萃取物，可透過減少體脂肪形成或堆積、降低體內慢性發炎反應，進而改善肥胖大鼠胰島素阻抗之現象，而產生維持肥胖鼠血糖穩定之效果。

Shen jin cao (Lycopodii Herba) is widely being used as a traditional Chinese medicine. Some reports claimed that it has anti-inflammatory and anti-oxidant capacity. Furthermore, several studies found that obesity-induced chronic inflammation could lead to abnormal glucose metabolism. However, whether Shen jin cao could improve metabolic disorders induced by obesity is still unclear. The purpose of this study is to investigate the effects of Shen jin cao on body weight, body composition and glucose metabolism in Wistar rats fed with a high-fat diet. We separate all rats into two groups, the control group (C) and the high-fat diet group (F), respectively. Firstly, the rats were induced to obese state by feeding a high-fat diet for twelve-weeks and then separated them into four experimental groups, the F control group, low-dose (50mg/kg BW) Shen jin cao extract group, medium-dose (100mg/kg BW) Shen jin cao extract group and high-dose (200mg/kg BW) Shen jin cao extract group. All rats were sacrificed after a 27-weeks intervention period and samples of blood, heart, liver, kidney and epididymal fat were collected and weighed. Fasting blood glucose, insulin, adiponectin, leptin, inflammatory markers, lipid profiles and activity of AST and ALT also were measured in serum samples. We found that the final body weight, weight gain, absolute weight of epididymal fat pad, heart and liver, AST and ALT activity, serum concentration of insulin, fasting glucose, adiponectin, leptin, triglyceride, TNF- and MCP-1 in high-fat diet (F) group are significantly higher than the control group, suggesting the abnormal parameters, including obesity, insulin resistance and chronic inflammation have been induced successfully by feeding high-fat diet in this rat model. After supplementation for 27 weeks, the final body weight, weight gain, ALT activity, concentration of insulin, fasting glucose, adiponectin, leptin, triglyceride, TNF- and MCP-1 all decreased significantly in Shen jin cao extract supplemented groups. In conclusion, supplement of high-dose (200mg/kg BW) Shen jin cao extract to obese rats may reduce their body weight, body fat accumulation, chronic inflammation, insulin resistance and hence is beneficial for their glycemic control.

目錄 I
表目錄 IV
圖目錄 V
中文摘要 VI
英文摘要 VII
第一章 前言 1
第二章、文獻回顧 2
第一節、肥胖 (Obesity) 2
第二節、高脂飲食與肥胖 3
第三節、 高脂飲食與疾病 4
一、代謝症候群 (Metabolic syndrome) 4
二、高血糖 (Hyperglycemia) 5
三、胰島素阻抗 (Insulin resistance) 5
四、慢性發炎 (Chronic inflammation) 6
五、非酒精性脂肪肝 (Nonalcoholic steatohepatitis, NASH) 7
六、心血管疾病 (Cardiovascular diseases) 8
七、高血壓 8
八、癌症 9
第四節、中醫學與肥胖 9
一、中醫肥胖觀 9
二、中醫治療肥胖症 10
第五節、伸筋草之介紹 11
一、植物特性 11
二、伸筋草藥理介紹 12
三、伸筋草相關研究 12
第六節、研究目的 13
第三章、研究材料與方法 14
第一節、實驗材料 14
一、動物飼料製備 14
二、試驗品 14
三、儀器、試藥及試劑組 15
第二節、動物實驗及實驗設計 16
一、動物試驗與實驗設計 16
二、非管制類麻醉藥之製備 16
三、動物犧牲與樣品採集 16
第三節、實驗分析方法 17
一、空腹血糖值分析 17
二、血清胰島素測定 17
三、血清瘦素之分析 18
四、血清脂聯素之分析 19
五、各項血脂項目測定 20
六、肝功能測定 21
七、血清發炎指標之分析 21
第四章、結果 24
第一節、生理及臟器重量之分析結果 24
一、伸筋草對高脂飲食誘發肥胖大鼠體重、攝食及飲水量之影響 24
二、伸筋草對高脂飲食誘發肥胖大鼠臟器重量之影響 24
第二節、血糖代謝之分析結果 25
一、伸筋草對高脂飲食誘發肥胖大鼠空腹血糖之影響 25
二、伸筋草對高脂飲食誘發肥胖大鼠血清胰島素之影響 25
三、伸筋草對高脂飲食誘發肥胖大鼠血清瘦素之影響 25
四、伸筋草對高脂飲食誘發肥胖大鼠血清脂聯素之影響 25
第三節、血脂之分析結果 26
一、伸筋草對高脂飲食誘發肥胖大鼠血清三酸甘油酯之影響 26
二、伸筋草對高脂飲食誘發肥胖大鼠血清總膽固醇之影響 26
第四節、肝功能之分析結果 26
一、伸筋草對高脂飲食誘發之肥胖大鼠血清天門冬胺酸轉胺酶及丙胺酸轉胺酶活性之結果 26
第五節、發炎指標之分析結果 27
一、伸筋草對高脂飲食誘發之肥胖大鼠血清TNF-α濃度之結果 27
二、伸筋草對高脂飲食誘發之肥胖大鼠血清MCP-1濃度之結果 27
第五章、討論 35
第一節、高脂飲食誘發肥胖之生成 35
第二節、伸筋草對高脂飲食誘發肥胖大鼠生長狀況之影響 36
第三節、伸筋草對高脂飲食誘發肥胖大鼠臟器之影響 37
第四節、伸筋草對高脂飲食誘發肥胖大鼠血糖代謝之影響 38
第五節、伸筋草對高脂飲食誘發肥胖大鼠血脂代謝之影響 40
第六節、伸筋草對高脂飲食誘發肥胖大鼠肝功能之影響 40
第七節、伸筋草對高脂飲食誘發肥胖大鼠發炎反應之影響 41
第六章、結論 42
第七章、參考文獻 43

丁書文、李曉、李運倫、陳守強 (2004)。心系疾病中的熱毒學說。中國醫藥學報。
李欣珮 (2011)。Histidine對脂質代謝的影響-高飽和脂質之動物模式。中國醫藥大學營養學系研究所碩士論文。
施穎 (2010)。Histidine和Carnosine對攝取高飽和油脂飲食老鼠的影響。中國醫藥大學營養學系研究所碩士論文。
孫玉安、段文若、李德愛 (2003)。實用內分泌代謝疾病藥物治療學。人民衛生出版社。北京。
高美丁 (2011)。膳食療養學三版。華格納企業。台中
崔博樂、李怡、張軍、米逸 (2009)。論肥胖與代謝綜合征的中醫學認識。北京醫藥。北京。
傅燕鳳 (2008)。世界藥用植物圖鑑。貓頭鷹出版。台北。
楊維傑 (1990)。黃帝內精靈樞譯解。志遠書局。台北
潘文涵 (2009)。國民營養健康狀況變遷調查2004-2008。行政院衛生福利部。
潘文涵、葉文婷、胡啟民、何橈通 (1998)。國民營養健康狀況變遷調查1993-1996台灣地區糖尿病之盛行率及認知狀況。行政院衛生福利部。
Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883-889.
Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87(1):1-16.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
Baird JD. Diabetes mellitus and obesity. Proc Nutr Soc. 1973;32(3):199-204.
Berry EM, Hirsch J, Most J, Thornton J. The role of dietary fat in human obesity. Int J Obes 1986;10(2):123-131.
Corbett SW, Stern JS, Keesey RE. Energy expenditure in rats with diet-induced obesity. Am J Clin Nutr. 1986;44(2):173-180.
Crescenzo R, Bianco F, Coppola P, Mazzoli A, Valiante S, Liverini G, et al. Adipose tissue remodeling in rats exhibiting fructose-induced obesity. Eur J Nutr. 2014;53(2):413-419.
Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188-2194.
Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4-7.
Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887.
Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293-300.
DiPietro L, Katz LD, Nadel ER. Excess abdominal adiposity remains correlated with altered lipid concentrations in healthy older women. Int J Obes. 1999;23(4):432-436.
Efferth T, Kaina B. Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Curr Drug Metab. 2011;12(10):989-996.
Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology. 2004;40(1):185-194.
Flier JS, Maratos-Flier E. Obesity and the hypothalamus: Novel peptides for new pathways. Cell. 1998;92(4):437-440.
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847-850.
Friedman JM, Leibel RL. Tackling a weighty problem. Cell. 1992;69(2):217-220.
Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol. 2006;54(7):375-386.
Fungwe TV, Cagen LM, Cook GA, Wilcox HG, Heimberg M. Dietary cholesterol stimulates hepatic biosynthesis of triglyceride and reduces oxidation of fatty acids in the rat. J Lipid Res. 1993;34(6):933-941.
Glaser C, Heinrich J, Koletzko B. Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism. Metab Clin Exp. 2010;59(7):993-999.
Ha SK, Kim J, Chae C. Role of AMP-activated Protein Kinase and Adiponectin during Development of Hepatic Steatosis in High-fat Diet-induced Obesity in Rats. J Comp Pathol. 2011;145(1):88-94.
Hajer GR, Van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-2971.
Handjieva-Darlenska T, Boyadjieva N. The effect of high-fat diet on plasma ghrelin and leptin levels in rats. J Physiol Biochem. 2009;65(2):157-164.
Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nut Res Rev. 2010;23(2):270-299.
Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol. 2009;15(25):3073-3085.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes. 2003;27(SUPPL. 3):S53-S55.
Kennedy A, Martinez K, Chuang CC, Lapoint K, Mcintosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: Mechanisms of action and implications. J Nutr. 2009;139(1):1-4.
Kim JH, Jae EK, Liu HY, Cao W, Chen J. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem. 2008;283(2):708-715.
Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: A review. Obes Rev. 2007;8(1):21-34.
Konrath EL, Neves BM, Lunardi PS, Passos CDS, Simões-Pires A, Ortega MG, et al. Investigation of the in vitro and ex vivo acetylcholinesterase and antioxidant activities of traditionally used Lycopodium species from South America on alkaloid extracts. J Ethnopharmacol. 2012;139(1):58-67.
Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45(4):602-607.
Kuhlow D, Zarse K, Voigt A, Schulz TJ, Petzke KJ, Schomburg L, et al. Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice. Eur J Nutr. 2010;49(7):417-427.
Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21(6):961-967.
Levin BE, Dunn-Meynell AA. Reduced central leptin sensitivity in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2002;283(4 52-4):R941-R948.
Lightman SL, Everitt BJ. Water excretion. Neuroendocrinology. 1986;197-206.
Lin JM, Lin CC, Chiu HF, Yang JJ, Lee SG. Evaluation of the anti-inflammatory and liver-protective effects of anoectochilus formosanus, ganoderma lucidum and gynostemma pentaphyllum in rats. Am J Chin Med. 1993;21(1):59-69.
Lin SC, Lin YH, Chen CF, Chung CY, Hsu SH. The Hepatoprotective and Therapeutic Effects of Propolis Ethanol Extract on Chronic Alcohol-induced Liver Injuries. Am J Chin Med. 1997;25(3-4):325-332.
Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab. 2009;94(9):3543-3549.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-184.
Malecka-Tendera E, Mazur A. Childhood obesity: A pandemic of the twenty-first century. Int J Obes. 2006;30(SUPPL. 2):S1-S3.
Markowitz JS, Von Moltke LL, Donovan JL. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol Nutr Food Res. 2008;52(7):747-754.
Mathias RA, Vergara C, Gao L, Rafaels N, Hand T, Campbell M, et al. FADS genetic variants and ω-6 polyunsaturated fatty acid metabolism in a homogeneous island population. J Lipid Res. 2010;51(9):2766-2774.
Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP. Visceral obesity and the heart. Int J Biochem Cell Biol. 2008;40(5):821-836.
Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(2):131-141.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-4200.
Mohankumar SMJ, King A, Shin AC, Sirivelu MP, Mohankumar PS, Fink GD. Developmental programming of cardiovascular disorders: Focus on hypertension. Rev Endocr Metab Disord. 2007;8(2):115-125.
Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: From the perspective of a vicious triangle. Int J Obes. 2002;26(SUPPL. 2):S28-S38.
Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 2008;31(3):562-568.
Muthusamy T, Murugesan P, Balasubramanian K. Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat. Metab Clin Exp. 2009;58(11):1581-1592.
Nam TW, Cho SH, Shin D, Kim JH, Jeong JY, Lee JH, et al. The Escherichia coli glucose transporter enzyme IICBGlc recruits the global repressor Mlc. EMBO J. 2001;20(3):491-498.
Nistor Baldea LA, Martineau LC, Benhaddou-Andaloussi A, Arnason JT, Lévy É, Haddad PS. Inhibition of intestinal glucose absorption by anti-diabetic medicinal plants derived from the James Bay Cree traditional pharmacopeia. J Ethnopharmacol. 2010;132(2):473-482.
Orellana RA, O'Connor PMJ, Bush JA, Suryawan A, Thivierge MC, Nguyen HV, et al. Modulation of muscle protein synthesis by insulin is maintained during neonatal endotoxemia. Am J Physiol Endocrinol Metab. 2006;291(1):E159-E166.
Orhan I, Küpeli E, Şener B, Yesilada E. Appraisal of anti-inflammatory potential of the clubmoss, Lycopodium clavatum L. J Ethnopharmacol. 2007;109(1):146-150.
Pathak S, Banerjee A, Khuda-Bukhsh A. Efficacy of ethanolic spore extract of Lycopodium clavatum in reducing induced hepatotoxicity and genotoxicity in mice. Int J Biol Chem Sci. 2010;4(3):770-781.
Peng Y, Rideout D, Rakita S, Sajan M, Farese R, You M, et al. Downregulation of Adiponectin/AdipoR2 is associated with steatohepatitis in obese mice. J Gastrointest Surg. 2009;13(11):2043-2049.
Phillips CM, Kesse-Guyot E, Mcmanus R, Hercberg S, Lairon D, Planells R, et al. High dietary saturated fat intake accentuates obesity risk associated with the fat mass and obesity-associated gene in adults. J Nutr. 2012;142(5):824-831.
Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: Modulation by nutrients and inflammation. J Clin Invest. 2008;118(9):2992-3002.
Schwartz MW, Woods SC, Porte Jr. D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661-671.
Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology. 2007;132(6):2169-2180.
Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92(3):1023-1033.
Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol. 2008;49(4):600-607.
Stafford M, Cummins S, Ellaway A, Sacker A, Wiggins RD, Macintyre S. Pathways to obesity: Identifying local, modifiable determinants of physical activity and diet. Soc Sci Med. 2007;65(9):1882-1897.
Staiger K, Staiger H, Weigert C, Haas C, Häring HU, Kellerer M. Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-κB activation. Diabetes. 2006;55(11):3121-3126.
Stolk RP, Meijer R, Mali WP, Grobbee DE, van der Graaf Y. Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr. 2003;77(4):857-860.
Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121(6):2094-2101.
Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1139-1142.
Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90(1):23-46.
Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541-3546.
Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30(8):2119-2121.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836-1846.
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-709.
Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg. 2011;54(3):819-831.
Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med. 2003;4(4):228-236.
Woods SC, Seeley RJ, Porte Jr. D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science. 1998;280(5368):1378-1383.
World Health Organization: Obesity and overweight [webpage]. Available from http://www.who.int/mediacentre/factsheets/fs311/en/. Revised January 2015.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-1830.
Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339.
Yumuk VD, Yumuk PF. What links obesity to cancer? Indoor Built Environ. 2005;14(6):527-532.
Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes. 2007;31(9):1420-1428.